A group of researchers with UCLA developed a spray gel that contains immune-stimulating drugs.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
It’s not hard to see how precision medicine will re-make the world of research and development and manufacturing and distribution for pharmaceutical and medical product companies. But it will make new demands on the supply chains of these organizations.
The benefits of statins in reducing the odds of heart attacks and strokes far outweigh any risks of side effects, according to a scientific statement released by the American Heart Association.
Axovant Sciences’ Phase II trial of nelotanserin for the treatment of REM sleep behavior disorder in patients with Lewy body dementia failed to meet the experimental drug’s primary efficacy endpoint.
AstraZeneca’s immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head & neck cancer.
Supernus Pharmaceuticals’ experimental drug for attention deficit hyperactivity disorder met the main goal of reducing symptoms in affected children from 6 to 11 years of age in two late-stage studies.
AbbVie halted a Phase III trial evaluating rovalpituzumab tesirine as a second-line therapy for advanced small-cell lung cancer after an Independent Data Monitoring Committee called for the stoppage due to shorter overall survival in the Rova-T arm.
Researchers at Flinders University in Australia – working with mice – removed a single gene known as RCAN1 and then fed them a variety of diets, including a high-fat diet. The mice did not gain weight, even after dramatically overeating high-fat foods over several weeks.
Researchers from the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology identified a nano-scaled DNA signature that seems to be common to all cancers.
Bayer halted trials testing the experimental uterine fibroids treatment vilaprisan, which the company previously expected to generate peak annual sales of more than 1 billion euros ($1.1 billion), citing the risk of side effects.
In What Could Be an Alzheimer’s Breakthrough, UCLA Scientists Link Specific Gene Mutations to Dementia
Researchers with the University of California, Los Angeles (UCLA) Health Sciences have identified two major groups of genes that, when mutated, results in overproduction of the tau protein, at least in mice.